Enterprise Value

182.8M

Cash

35.41M

Avg Qtr Burn

-8.561M

Short % of Float

0.89%

Insider Ownership

34.72%

Institutional Own.

16.46%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
CAN-2409 Details
Prostate cancer, Cancer, Solid tumor/s

Phase 3

Data readout

Phase 2

Data readout

CAN-2409 Details
Prostate cancer, Cancer, Solid tumor/s

Phase 2

Data readout

CAN-2409 + Valacyclovir w/ PD-(L)1 targeting agents Details
Lung cancer, Cancer, Solid tumor/s, Non-small cell lung carcinoma

Phase 2

Data readout

CAN-3110 Details
Solid tumor/s, Cancer, Glioma

Phase 1b

Data readout

CAN-2409 + Opdivo Details
Cancer, Glioma, Solid tumor/s

Failed

Discontinued